Lupin spins out two oncology programs to Kaveri Therapeutics to advance its oncology strategy
Global pharma major Lupin, announced the strategic spin-out of two oncology programs – LNP7457 (PRMT5) and LNP8701 (SOS1), …
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
oncology
Zydus to acquire Assertio in all-cash tender offer
Assertio is focused on specialty and oncology supportive-care therapies
Large pharma drug licensing from China reaches record high at 28 per cent in 2024, reveals…
Innovator drug deals involving Chinese biopharma reach $41.5 billion as licensing overtakes M&A for pipeline expansion, notes…
Belgian Economic Mission to India highlights collaborations in lifesciences sector
Bringing together leaders, researchers, and stakeholders in the life sciences sector, this event aims to showcase how Belgium and…
VeGen Labs secures BIRAC funding to advance KRAS Inhibitor
The BIRAC funding will enable comprehensive toxicology assessments, a critical step in preparing for IND submission with…
Zydus Lifesciences signs agreement with Synthon BV for 505(B)(2) oncology product
Zydus to handle NDA submission and commercialisation in the US; Synthon to lead development and manufacturing
Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT…
ISB 2001 demonstrated an ORR of 83 per cent in heavily pretreated patients treated at active doses (0.05 mg/kg and higher)
Sun Pharma and Philogen sign global licensing agreement for Fibromun
Agreement focuses on global commercialisation of anti-cancer immunotherapy
Lupin launches Doxorubicin Hydrochloride Liposome Injection in the United States
Lupin expands oncology portfolio with the launch of a generic version of Doxil in the U.S.
Our aim is to tailor our oncology portfolio to address the most pressing needs in India
Pratima Reddy, Country Speaker for Merck India & MD, Merck Specialties elaborates on the company’s partnerships with national…